DoMore Diagnostics pricing
No rates are published. The value case is framed in terms a payer can cost: the company states that adjuvant chemotherapy gives no benefit to 96 to 98 percent of stage II and 80 percent of stage III colorectal patients, so the saving is avoided chemotherapy and its side effects rather than workflow time, and it lists rapid turnaround among the test's features.
How DoMore Diagnostics pricing works
- Pricing model
- Undisclosed. No per test or platform rates published; ordering through the vendor's order page or the named host platforms.
- Implementation
- Not disclosed. Delivered inside existing image management systems through Sectra's Amplifier Marketplace, PathAI's AISight and Proscia's Concentriq Dx.
- Business associate agreement
- Not disclosed. No processor position or data processing terms published; CE-IVDD marked, with no FDA clearance.
The test is available through Sectra's Amplifier Marketplace, PathAI's AISight and Proscia's Concentriq Dx, and the site has an order page, but no per test fee or platform terms are published. The product page states CE-IVDD marking, under the older IVD directive rather than the IVDR.
DoMore Diagnostics pricing against its alternatives
Published prices for DoMore Diagnostics and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- DDoMore DiagnosticsNo published price
- VValar LabsPer test, ordered from the vendor's own laboratory
- AArteraAINo list price published; patient cost $0 to $285 under the financial assistance program, and none for covered Medicare patients
- SStratipathNo published price
- PProsciaNo published price
- AAiosynNo published price
- PPrimaaNo published price
- PPreciseDxNo published price
- PPathAINo published price
DoMore Diagnostics pricing, answered
How much does DoMore Diagnostics cost?
DoMore Diagnostics does not publish a price. The value case is framed in terms a payer can cost: the company states that adjuvant chemotherapy gives no benefit to 96 to 98 percent of stage II and 80 percent of stage III colorectal patients, so the saving is avoided chemotherapy and its side effects rather than workflow time, and it lists rapid turnaround among the test's features.
Does DoMore Diagnostics charge an implementation fee?
Not disclosed. Delivered inside existing image management systems through Sectra's Amplifier Marketplace, PathAI's AISight and Proscia's Concentriq Dx.
Does DoMore Diagnostics offer a business associate agreement?
Not disclosed. No processor position or data processing terms published; CE-IVDD marked, with no FDA clearance.